A 24-week trial showed up to a 52% reduction in urine protein and a 30% reduction in kidney inflammation among participants. study: Semaglutide in patients with...
Researchers from Massachusetts General Brigham and colleagues found that the use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023, and surgery...
Survey results UCLA scientists have identified the protein GPNMB as a key regulator in the heart's healing process after a heart attack. Using animal models, they...
Semaglutide is associated with a 40-70% lower risk of being diagnosed with Alzheimer's disease for the first time. Type 2 diabetic patients compared to other diabetes...
New research suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), used to treat diabetes and obesity, may also be repurposed for opioid use disorder (OUD) and...
New research published in scientific journal addiction People with opioid or alcohol use disorder (OUD, AUD) who take Ozempic or similar drugs to treat diabetes or...
Recent Comments